Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Non-Current Debt (2016 - 2022)

Plus Therapeutics (PSTV) has disclosed Non-Current Debt for 9 consecutive years, with $3.8 million as the latest value for Q4 2022.

  • Quarterly Non-Current Debt changed N/A to $3.8 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Dec 2022, changed N/A year-over-year, with the annual reading at $3.8 million for FY2022, N/A changed from the prior year.
  • Non-Current Debt for Q4 2022 was $3.8 million at Plus Therapeutics, down from $4.1 million in the prior quarter.
  • The five-year high for Non-Current Debt was $4.7 million in Q1 2022, with the low at $3.8 million in Q4 2022.